Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...

Indianapolis-based OrthoIndy treated the first patients with Theradaptive's OsteoAdapt SP spinal fusion implant as part of an ongoing clinical trial. The Phase I/II Oasis trial is asssing the safety ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

The upcoming clinical trial conferences will host talks on supply chain resilience, AI’s growing role and forging industry ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company’s leadership in improving access to medicines around ...

Ocugen has announced positive Phase 1 trial results for OCU410, a one-time gene therapy for geographic atrophy secondary to ...

(TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Q3 2024 Earnings Call Transcript November 18, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx ...

Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling.

The $1.2 billion company has some of the biggest podcast bros and athletes touting its praises. Is the greens powder the ...